Eli Lilly (LLY) Receivables - Net (2016 - 2025)
Eli Lilly (LLY) has disclosed Receivables - Net for 17 consecutive years, with $17.8 billion as the latest value for Q4 2025.
- For the quarter ending Q4 2025, Receivables - Net rose 61.37% year-over-year to $17.8 billion, compared with a TTM value of $17.8 billion through Dec 2025, up 61.37%, and an annual FY2025 reading of $17.8 billion, up 61.37% over the prior year.
- Receivables - Net was $17.8 billion for Q4 2025 at Eli Lilly, up from $16.1 billion in the prior quarter.
- Across five years, Receivables - Net topped out at $17.8 billion in Q4 2025 and bottomed at $5.6 billion in Q1 2021.
- Average Receivables - Net over 5 years is $9.1 billion, with a median of $7.7 billion recorded in 2023.
- The sharpest move saw Receivables - Net rose 3.34% in 2022, then surged 61.37% in 2025.
- Year by year, Receivables - Net stood at $6.7 billion in 2021, then grew by 3.34% to $6.9 billion in 2022, then skyrocketed by 31.82% to $9.1 billion in 2023, then grew by 21.07% to $11.0 billion in 2024, then soared by 61.37% to $17.8 billion in 2025.
- Business Quant data shows Receivables - Net for LLY at $17.8 billion in Q4 2025, $16.1 billion in Q3 2025, and $14.2 billion in Q2 2025.